Lipoprotein(a) in children and adolescence

Pediatric Endocrinology Reviews

Volumn 1, Issue 2, 2003, Pages 109-119

  Wang, Xing Li ^a   Wang, Jian ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

(IGF 1) growth hormone; Lp (a); Vascular diseases

Indexed keywords

CARRIER PROTEIN; CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLASMINOGEN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENE CONTROL; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; VASCULAR DISEASE;

CHILD; HUMANS; LIPOPROTEIN(A); RISK FACTORS; VASCULAR DISEASES;

EID: 12344324102     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26
2. Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-10
3. Berg K. Comparative studies on the Lp and Ag serum type systems of human beta-lipoprotein. Bibl Haematol 1965;23:385-8
4. Berg K. Lp(a) lipoprotein: an overview. Chem Phys Lipids 1994;67-68:9-16
5. Wang XL, Tam C, McCredie RM, Wilcken DE. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994;89:1974-81
6. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem 1998;44:2301-6
7. Hopkins PN, Hunt SC, Schreiner PJ, Eckfeldt JH, Borecki IB, Ellison CR, Williams RR, Siegmund KD. Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. Atherosclerosis 1998;141:333-45
8. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, Finardi G, Geroldi D. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 1999;33:157-63
9. Gazzaruso C, Buscaglia P, Garzaniti A, Falcone C, Mariotti S, Savino S, Bonetti G, Finardi G, Geroldi D. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens 1997;15:227-35
10. Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, De Amici E, Geroldi D, Fratino P. Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care 2002;25:1418-24
11. Dahlen GH, Weinehall L, Stenlund H, Jansson JH, Hallmans G, Huhtasaari F, Wall S. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med 1998;244:425-30
12. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998;19:1355-64
13. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. Jama 1994;271:999-1003
14. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994;90:1688-95
15. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. Jama 1996;276:544-8
16. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19
17. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-53
18. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390-7
19. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67
20. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, Wamala SP, Eriksson M, Belkic K, Kirkeeide R, Svane B, Ryden L. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997;95:329-34
21. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5
22. Wang XL, Cranney G, Wilcken DE. Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients. Aust N Z J Med 2000;30:333-8
23. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92
24. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994;93:50-5
25. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460-2
26. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60
27. Rainwater DL, Kammerer CM, VandeBerg JL. Evidence that multiple genes influence baseline concentrations and diet response of Lp(a) in baboons. Arterioscler Thromb Vasc Biol 1999;19:2696-700
28. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB, Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993;91:443-7
29. Rainwater DL, Lanford RE. Production of lipoprotein(a) by primary baboon hepatocytes. Biochim Biophys Acta 1989;1003:30-5
30. Utermann G, Kraft HG. Lipoprotein(a) in cirrhosis. Bmj 1992;305:185
31. Black IW, Wilcken DE. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353-7
32. Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996;9:533-7
33. Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H. Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid-sensitive nephrotic syndrome. Nephron 2002;92:807-11
34. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10:133-41
35. Dullaart RP, van Doormaal JJ, Hoogenberg K, Sluiter WJ. Triiodothyronine rapidly lowers plasma lipoprotein (a) in hypothyroid subjects. Neth J Med 1995;46:179-84
36. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93
37. Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998;18:1335-41
38. Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 1999;42:41-4
39. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997;136:377-81
40. Oscarsson J, Ottosson M, Wiklund O, Marin P, Vikman-Adolfsson K, Bjorntorp P, Eden S. Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men. Clin Endocrinol (Oxf) 1994;41:109-16
41. Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B. Hormonal regulation of serum lippprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. Arterioscler Thromb Vasc Biol 1995;15:847-9
42. Johannsson G, Oscarsson J, Rosen T, Wiklund O, Olsson G, Wilhelmsen L, Bengtsson BA. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995;15:2142-50
43. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism 1996;45:1263-6
44. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Eden S, Wiklund O. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol (Oxf) 1995;42:673-6
45. Wang XL, Wang J, Rainwater DL. Acute effects of insulin-like growth factor-1 and recombinant growth hormone on lipoprotein(a) levels in baboons. Metabolism 2002;51:508-13
46. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40
47. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2153-61
48. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-65
49. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 1988;78:41-6
50. Sandholzer C, Mailman DM, Sana N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-14
51. Gavish D, Azrolan N, Breslow JL. Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 1989;84:2021-7
52. White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for "null" lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem 1994;269:9060-6
53. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 1993;90:1369-73
54. Mancini FP, Mooser V, Guerra R, Hobbs HH. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995;4:1535-42
55. Malgaretti N, Acquati F, Magnaghi P, Bruno L, Pontoglio M, Rocchi M, Saccone S, Della Valle G, D'Urso M, LePaslier D, et al. Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region. Proc Natl Acad Sci U S A 1992;89:11584-8
56. Bopp S, Kochl S, Acquati F, Magnaghi P, Petho-Schramm A, Kraft HG, Utermann G, Muller HJ, Taramelli R. Ten allelic apolipoprotein[a] 5′ flanking fragments exhibit comparable promoter activities in HepG2 cells. J Lipid Res 1995;36:1721-8
57. Hixson JE, Jett C, Birnbaum S. Identification of promoter sequences in the 5′ untranslated region of the baboon apolipoprotein[a] gene. J Lipid Res 1996;37:2324-31
58. Cox LA, Jett C, Hixson JE. Molecular basis of an apolipoprotein[a] null allele: a splice site mutation is associated with deletion of a single exon. J Lipid Res 1998;39:1319-26
59. Ichinose A, Kuriyama M. Detection of polymorphisms in the 5′-flanking region of the gene for apolipoprotein(a). Biochem Biophys Res Commun 1995;209:372-8
60. Ichinose A. Characterization of the apolipoprotein(a) gene. Biochem Biophys Res Commun 1995;209:365-71
61. Suzuki K, Kuriyama M, Saito T, Ichinose A. Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5′-flanking region. J Clin Invest 1997;99:1361-6
62. Lawn RM. How often has Lp(a) evolved? Clin Genet 1996;49:167-74
63. Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD, Fong KJ, Meer K, Patthy L. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995;270:24004-9
64. Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci U S A 1997;94:11992-7
65. VandeBerg JL, Weitkamp L, Kammerer CM, Weill P, Aivaliotis MJ, Rainwater DL. Linkage of plasminogen (PLG) and apolipoprotein(a) (LPA) in baboons. Genomics 1991;11:925-30
66. Komai N, Morishita R, Yamada S, Oishi M, Iguchi S, Aoki M, Sasaki M, Sakurabayashi I, Higaki J, Ogihara T. Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension 2002;40:310-4
67. Morishita R, Yamada S, Higaki J, Tomita N, Kida I, Aoki M, Moriguchi A, Hayashi S, Sakurabayashi I, Kaneda Y, Ogihara T. Conditioned medium from HepG2 cells transfected with human apolipoprotein(a) gene stimulates growth of human vascular smooth muscle cells: effects of overexpression of human apolipoprotein(a) gene. Hypertension 1998;32:215-22
68. Yano Y, Seishima M, Tokoro Y, Noma A. Stimulatory effects of lippprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta 1998;1393:26-34
69. Papagrigorakis E, Iliopoulos D, Asimacopoulos PJ, Safi HJ, Weilbaecher DJ, Ghazzaly KG, Nava ML, Gaubatz JW, Morrisett JD. Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet 1997;52:262-71
70. Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 1997;45:559-68
71. Durrington PN. Lipoprotein (a). Baillieres Clin Endocrinol Metab 1995;9:773-95
72. Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci U S A 1990;87:6204-7
73. Laron Z, Wang XL. Growth hormone, lipoprotein(a) and cardiovascular disease. Eur Heart J 1998;19:204-6
74. de la Pena-Diaz A, Izaguirre-Avila R, Angles-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000;31:353-9
75. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 2000;11:1889-95
76. Djurovic S, Thelle DS, Ringstad J, Christensen B, Berg K. Altered serum concentrations of TGF-beta 1 and Lp(a) lipoprotein and their correlation in patients with first acute myocardial infarction. Nutr Metab Cardiovasc Dis 1999;9:250-4
77. Morishita R, Yamamoto K, Yamada S, Matsushita H, Tomita N, Sakurabayashi I, Kaneda Y, Moriguchi A, Higaki J, Ogihara T. Stimulatory effect of lipoprotein (a) on proliferation of human mesangial cells: role of lipoprotein (a) in renal disease. Biochem Biophys Res Commun 1998;249:313-20
78. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998;18:984-90
79. Djurovic S, Schjetlein R, Wisloff F, Haugen G, Husby H, Berg K. Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. Clin Genet 1997;52:371-6
80. Sato Y, Kobori S, Sakai M, Yano T, Higashi T, Matsumura T, Morikawa W, Terano T, Miyazaki A, Horiuchi S, Shichiri M. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-beta activation. Atherosclerosis 1996;125:15-26
81. Kramer-Guth A, Greiber S, Pavenstadt H, Quaschning T, Winkler K, Schollmeyer P, Wanner C. Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix. Kidney Int 1996;49:1250-61
82. Miyata M, Biro S, Kaieda H, Tanaka H. Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett. 1995;377:493-6
83. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439-45
84. Shewmon DA, Stock JL, Abusamra LC, Kristan MA, Baker S, Heiniluoma KM. Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 1994;43:531-2
85. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266-74
86. Thommes KB, Hoppe J, Vetter H, Sachinidis A. The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signalling pathways. Exp Cell Res 1996;226:59-66
87. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Repine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 1994;89:1511-7
88. Yamamoto M, Yamamoto K. Growth regulation in primary culture of rabbit arterial smooth muscle cells by platelet-derived growth factor, insulin-like growth factor-I, and epidermal growth factor. Exp Cell Res 1994;212:62-8
89. Fu L, Jamieson DG, Usher DC, Lavi E. Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries. Atherosclerosis 2001;158:303-11
90. Wang XL, Wilcken DE, Dudman NP. Early expression of the apolipoprotein (a) gene: relationships between infants' and their parents' serum apolipoprotein (a) levels. Pediatrics 1992;89:401-6
91. Wang XL, Wilcken DE, Dudman NP. Neonatal apo A-I, apo B, and apo(a) levels in dried blood spots in an Australian population. Pediatr Res 1990;28:496-501
92. Wang XL, Wilcken DE, Dudman NP, Wang J. Changes of allele-specific expression of apo(a) gene in infants during first year of life. Lancet 1992;340:431
93. Wilcken DE, Wang XL, Greenwood J, Lynch J. Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents. J Pediatr 1993;123:519-26
94. Berenson GS, Srinivasan SR. Consideration of serum cholesterol in risk factor profiling for all young individuals. Nutr Metab Cardiovasc Dis 2001;11:1-9
95. Nicklas TA, von Duvillard SP, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa Heart Study. Int J Sports Med 2002;23:S39-43
96. Kelder SH, Osganian SK, Feldman HA, Webber LS, Parcel GS, Leupker RV, Wu MC, Nader PR. Tracking of physical and physiological risk variables among ethnic subgroups from third to eighth grade: the Child and Adolescent Trial for Cardiovascular Health cohort study. Prev Med 2002;34:324-33
97. Kimm SY, Pasagian-Macaulay A, Aston CE, McAllister AE, Glynn NW, Kamboh MI, Ferrell RE. Correlates of lipoprotein(a) levels in a biracial cohort of young girls: the NHLBI Growth and Health Study. J Pediatr 1999;135:169-76
98. Schulpis KH, Karikas GA, Gavrili S, Georgala S. Evaluation of serum lipoprotein(a) levels in Greek schoolchildren. Acta Paediatr 2001;90:225-6
99. Chu NF, Makowski L, Chang JB, Wang DJ, Liou SH, Shieh SM. Lipoprotein profiles, not anthropometric measures, correlate with serum lipoprotein(a) values in children: the Taipei children heart study. Eur J Epidemiol 2000;16:5-12
100. Wiegman A, Rodenburg J, de Jongh S, Defesche JC, Bakker HD, Kastelein JJ, Sijbrands EJ. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003;107:1473-8
101. Dirisamer A, Widhalm K. Lipoprotein(a) as a potent risk indicator for early cardiovascular disease. Acta Paediatr 2002;91:1313-7
102. Laskowska-Klita T, Szymczak E, Radomyska B. Serum homocysteine and lipoprotein (a) concentrations in hypercholesterolemic and normocholesterolemic children. Clin Pediatr (Phila) 2001;40:149-54
103. Torbus-Lisiecka B, Bukowska H, Jastrzebska M, Chelstowski K, Honczarenko K, Naruszewicz M. Lp(a), homocysteine and a family history of early ischemic cerebral stroke. Nutr Metab Cardiovasc Dis 2001;11:52-9
104. Schwandt P, Geiss HC, Haas GM. Global cardiovascular risk in children and their families: the Prevention Education Program (PEP), Nurnberg. Nutr Metab Cardiovasc Dis 2001;11:35-9
105. Strong JP, Zieske AW, Malcom GT. Lipoproteins and atherosclerosis in children: an early marriage? Nutr Metab Cardiovasc Dis 2001;11:16-22
106. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002;21:213-37
107. Glowinska B, Urban M, Koput A. Cardiovascular risk factors in children with obesity, hypertension and diabetes: lipoprotein(a) levels and body mass index correlate with family history of cardiovascular disease. Eur J Pediatr 2002;161:511-8
108. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein A. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999;94:3678-82
109. Nowak-Gottl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein A. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999;100:743-8
110. Nowak-Gottl U, Schobess R, Kurnik K, Schwabe D, Fleischhack G, Junker R. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood 2002;99:3476-7; author reply 3477-8
111. Gunczler P, Lanes R, Lopez E, Esaa S, Villarroel O, Reyel-Chion R. Cardiac mass and function, carotid artery intima-media thickness and lipoprotein (a) levels in children and adolescents with type 1 diabetes mellitus of short duration. J Pediatr Endocrinol Metab 2002;15:181-6
112. Cabrinety N, Pisonero MJ, Ajram J, Armenteras A, Cuatrecasas JM. Lipoprotein (a) in obese children with a family history of cardiovascular disease. J Pediatr Endocrinol Metab 2002;15:77-80
113. Noto D, Barbagallo CM, Cascio AL, Cefalu AB, Cavera G, Caldarella R, Marino G, Travail S, Cutaia I, Maringhini S, Notarbartolo A, Averna M. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome. Kidney Int 1999;55:2433-9
114. Nakahara C, Kobayashi K, Hamaguchi H, Kanemoto K, Kashiwagi R, Matsui A. Plasma lipoprotein (a) levels in children with minimal lesion nephrotic syndrome. Pediatr Nephrol 1999;13:657-61
115. Nakahara C, Nagata M, Watanabe T, Kobayashi K, Hamaguchi H, Kanemoto K, Kashiwagi R, Matsui A. Clinical significance of apolipoprotein (a) deposition in kidney diseases of children. Clin Nephrol 1999;52:131-8
116. Soulat T, Loyau S, Baudouin V, Maisonneuve L, Hurtaud-Roux MF, Schlegel N, Loirat C, Angles-Cano E. Effect of individual plasma lippprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000;20:575-84
117. Okosun IS, Dever GE, Choi ST. Low birth weight is associated with elevated serum lipoprotein(a) in white and black American children ages 5-11 y. Public Health 2002;116:33-8
118. Pulzer F, Haase U, Kratzsch J, Richter V, Rassoul F, Kiess W, Keller E. Lipoprotein(a) levels in formerly small-for-gestational-age children. Horm Res 1999;52:241-6
119. Badenhop RF, Wang XL, Wilcken DE. Angiotensin-converting enzyme genotype in children and coronary events in their grandparents. Circulation 1995;91:1655-8
120. Badenhop RF, Wang XL, Wilcken DE. Association between an angiotensinogen microsatellite marker in children and coronary events in their grandparents. Circulation 1996;93:2092-6
121. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsumi Y, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037-40
122. Morishita R, Yamada S, Yamamoto K, Tomita N, Kida I, Sakurabayashi I, Kikuchi A, Kaneda Y, Lawn R, Higaki J, Ogihara T. Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation 1998;98:1898-904
123. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). Jama 1995;274:1771-4
124. Habib SS, Aslam M, Naveed AK, Sattar A. Lippprotein (a) and glycaemic control in Pakistani subjects with diabetes mellitus. J Pak Med Assoc 2003;53:54-9
125. Chimienti G, Lamanuzzi BL, Nardulli M, Colacicco AM, Capurso A, La Gipia R, Scrutinio D, Pepe G. APO(a) variants and lipoprotein(a) in men with or without myocardial infarction. Exp Mol Pathol 2002;73:28-34
126. Schillinger M, Domanovits H, Ignatescu M, Exner M, Bayegan K, Sedivy R, Polterauer P, Laggner AN, Minar E, Kostner K. Lipoprotein (a) in patients with aortic aneurysmal disease. J Vasc Surg 2002;36:25-30
127. Katsouras CS, Karabina SA, Tambaki AP, Goudevenos JA, Michalis LK, Tsironis LD, Stroumbis CS, Elisaf MS, Sideris DA, Tselepis AD. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk 2001;8:311-7
128. Santos RD, Foronda A, Ramires JA, Maranhao RC. Levels of lipoprotein (a) in pulmonary arterial hypertension. Cardiol Young 2001;11:25-9
129. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-8
130. Singh S, Dwivedi S, Melkani GC, Rani C, Gaur SP, Mandal SK, Mahua J. Lipoprotein(a) and coronary heart disease in Indian population. J Assoc Physicians India 1999;47:1157-60
131. Gupta R, Kastia S, Rastogi S, Kaul V, Nagar R, Enas EA. Lipoprotein(a) in coronary heart disease: a case-control study. Indian Heart J 2000;52:407-10
132. Leowattana W, Mahanonda N, Bhuripanyo K, Pokum S, Worawattananon P. Correlation of serum lipoprotein(a) with the clinical presentation of Thai coronary artery disease patients. J Med Assoc Thai 2000;83:S194-8
133. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000;153:445-51
134. Peltier M, Iannetta Peltier MC, Sarano ME, Lesbre JP, Colas JL, Tribouilloy CM. Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis. Chest 2002;121:1589-94
135. Ramachandran A, Sathyamurthy I, Snehalatha C, Satyavani K, Sivasankari S, Misra J, Girinath MR, Viswanathan V. Risk variables for coronary artery disease in Asian Indians. Am J Cardiol 2001;87:267-71
136. Pantoni L, Sarti C, Pracucci G, Di Carlo A, Vanni P, Inzitari D. Lipoprotein(a) serum levels and vascular diseases in an older Caucasian population cohort. Italian Longitudinal Study on Aging (ILSA). J Am Geriatr Soc 2001;49:117-25
137. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000;20:2619-24
138. Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, Kurnik K, Schobess R, Nowak-Gottl U. Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet 2002;360:1540-5
139. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:1375-82
140. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002;252:27-35
141. Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol 2002;25:287-90
142. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163:377-84
143. Lundstam U, Herlitz J, Karlsson T, Linden T, Wiklund O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med 2002;251:111-8
144. Cantin B, Despres JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, Dagenais GR. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002;89:662-6
145. Wang W, Hu D, Lee ET, Fabsitz RR, Welty TK, Robbins DC, Yeh JL, Howard BV. Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol 2002;12:107-14
146. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
147. Seed M, Ayres KL, Humphries SE, Miller GJ. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 2001;110:22-7
148. Sweetnam PM, Bolton CH, Downs LG, Durrington PN, MacKness MI, Elwood PC, Yarnell JW. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest 2000;30:947-56